Screener
Spyre Therapeutics, Inc. SYRE Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Related party accounts payable | 50 | 14 |
| Total current liabilities | 85,162 | 58,685 |
| Non-current CVR liability | 6,690 | 3,860 |
| Other non-current liabilities | 1,290 | — |
| TOTAL LIABILITIES | 93,142 | 62,545 |
| Commitments and Contingencies (Notes 6 and 7) | ||
| STOCKHOLDERS’ EQUITY | ||
| Series A non-voting convertible preferred stock, $0.0001 par value; 1,086,341 shares authorized as of March 31, 2026 and December 31, 2025; 346,045 shares issued and outstanding as of March 31, 2026 and December 31, 2025. | 146,425 | 146,425 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s other non-current liabilities?
- Spyre Therapeutics, Inc. (SYRE) reported other non-current liabilities of $1.29M in Q1 2026.
- What is the long-term trend for Spyre Therapeutics, Inc.'s other non-current liabilities?
- Over 3 years (2020 to 2025), Spyre Therapeutics, Inc.'s other non-current liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $214K to $0.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Spyre Therapeutics, Inc.'s other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude